MX2022003110A - Anticuerpos biespecificos contra ceacam5 y cd3. - Google Patents

Anticuerpos biespecificos contra ceacam5 y cd3.

Info

Publication number
MX2022003110A
MX2022003110A MX2022003110A MX2022003110A MX2022003110A MX 2022003110 A MX2022003110 A MX 2022003110A MX 2022003110 A MX2022003110 A MX 2022003110A MX 2022003110 A MX2022003110 A MX 2022003110A MX 2022003110 A MX2022003110 A MX 2022003110A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antibodies against
antibodies
relates
ceacam5
Prior art date
Application number
MX2022003110A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Strein
Sara Majocchi
Original Assignee
Lamkap Bio Alpha AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamkap Bio Alpha AG filed Critical Lamkap Bio Alpha AG
Publication of MX2022003110A publication Critical patent/MX2022003110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022003110A 2019-09-18 2020-09-17 Anticuerpos biespecificos contra ceacam5 y cd3. MX2022003110A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902150P 2019-09-18 2019-09-18
EP19198124 2019-09-18
PCT/IB2020/058690 WO2021053587A1 (en) 2019-09-18 2020-09-17 Bispecific antibodies against ceacam5 and cd3

Publications (1)

Publication Number Publication Date
MX2022003110A true MX2022003110A (es) 2022-06-27

Family

ID=72615918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003110A MX2022003110A (es) 2019-09-18 2020-09-17 Anticuerpos biespecificos contra ceacam5 y cd3.

Country Status (18)

Country Link
US (2) US12441807B2 (https=)
EP (1) EP4013512B1 (https=)
JP (1) JP7701911B2 (https=)
KR (1) KR20220113353A (https=)
CN (1) CN114786776B (https=)
AU (1) AU2020350205A1 (https=)
BR (1) BR112022004995A2 (https=)
CL (1) CL2022000663A1 (https=)
CO (1) CO2022004685A2 (https=)
ES (1) ES2975528T3 (https=)
HR (1) HRP20240626T1 (https=)
HU (1) HUE067160T2 (https=)
IL (1) IL291482A (https=)
MX (1) MX2022003110A (https=)
PE (1) PE20221045A1 (https=)
PL (1) PL4013512T3 (https=)
RS (1) RS65480B1 (https=)
WO (1) WO2021053587A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
IL314916A (en) 2022-03-07 2024-10-01 Novimmune Sa Bispecific CD28 antibodies for targeted T cell activation
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
KR20250024741A (ko) 2022-03-23 2025-02-19 시나픽스 비.브이. 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
CN116925232A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 靶向ceacam和cd3的多特异性抗体及其用途
AU2023291779A1 (en) 2022-06-16 2024-10-17 Lamkap Bio Beta Ltd Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2024144400A1 (en) * 2022-12-30 2024-07-04 Merus N.V. Promiscuous cd3 binding molecules
US20250043001A1 (en) 2023-03-14 2025-02-06 Xencor, Inc. Anti-cd28 compositions
WO2025100827A1 (ko) * 2023-11-09 2025-05-15 주식회사 다안바이오테라퓨틱스 항 ceacam5 항체 및 이의 용도
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US20020165360A1 (en) 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
RU2769948C2 (ru) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
KR20090010580A (ko) 2007-07-24 2009-01-30 조용식 페트용 토이렛
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
PE20141017A1 (es) 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US20140242081A1 (en) 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
KR102100388B1 (ko) 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
DK3725807T3 (da) 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
CN106456748A (zh) 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
RU2689689C2 (ru) 2015-01-23 2019-05-28 Хеликс Байофарма Корпорейшн Конъюгаты антитело-уреаза для терапевтических целей
PT3277821T (pt) 2015-03-31 2019-10-31 Novimmune Sa Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos
PE20180484A1 (es) * 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
GB2546072B (en) 2016-01-05 2019-07-10 Bja Trading Ltd Attachment assembly and method of using same
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
KR102505253B1 (ko) 2016-04-15 2023-03-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
EP3454900A4 (en) 2016-05-09 2020-01-29 Celgene Corporation CD47 ANTIBODIES AND METHODS OF USE
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
WO2018053328A1 (en) * 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2018199593A1 (ko) 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체
WO2019054559A1 (ko) 2017-09-15 2019-03-21 엘지전자 주식회사 Brir/rir 파라미터화(parameterization)를 적용한 오디오 인코딩 방법 및 파라미터화된 brir/rir 정보를 이용한 오디오 재생 방법 및 장치
KR20200099135A (ko) 2017-12-14 2020-08-21 에프. 호프만-라 로슈 아게 Cea cd3 이중특이성 항체 및 pd-1 축 결합 길항제의 암 치료를 위한 투약 요법에서의 용도
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3

Also Published As

Publication number Publication date
US20260109779A1 (en) 2026-04-23
IL291482A (en) 2022-05-01
CO2022004685A2 (es) 2022-07-08
AU2020350205A1 (en) 2022-05-12
RS65480B1 (sr) 2024-05-31
JP7701911B2 (ja) 2025-07-02
CN114786776B (zh) 2026-03-24
KR20220113353A (ko) 2022-08-12
CA3150265A1 (en) 2021-03-25
CN114786776A (zh) 2022-07-22
EP4013512C0 (en) 2024-02-14
JP2022548947A (ja) 2022-11-22
US20230136228A1 (en) 2023-05-04
BR112022004995A2 (pt) 2022-06-21
EP4013512A1 (en) 2022-06-22
CL2022000663A1 (es) 2023-01-06
EP4013512B1 (en) 2024-02-14
HRP20240626T1 (hr) 2024-08-02
HUE067160T2 (hu) 2024-10-28
WO2021053587A1 (en) 2021-03-25
PE20221045A1 (es) 2022-06-22
PL4013512T3 (pl) 2024-06-10
ES2975528T3 (es) 2024-07-08
US12441807B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
MX2022003110A (es) Anticuerpos biespecificos contra ceacam5 y cd3.
PH12020551211A1 (en) Antibodies binding to gprc5d
MY206610A (en) Antibodies binding to gprc5d
PH12021551484A1 (en) Antibodies binding to cd3
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
PH12022500024A1 (en) Immune activating fc domain binding molecules
PH12022500027A1 (en) Antibodies binding to cd3
PH12020550952A1 (en) Antibodies binding to hla-a2/wt1
MX2022007635A (es) Anticuerpos que se unen a hla-a2/mage-a4.
PH12019502274A1 (en) Antibodies binding to steap-1
PH12019502640A1 (en) Antibodies specific for flt3 and their uses
AU2018337142A8 (en) Novel bispecific CD3/CD19 polypeptide complexes
MX2022016069A (es) Anticuerpos que se unen a cd3 y cd19.
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
MX2022001830A (es) Anticuerpos terapeuticos y sus usos.
MX2023007220A (es) Anticuerpos biespecificos contra el antigeno carcinoembrionario humano (ceacam5) y el cumulo de diferenciacion 47 (cd47).
NZ708182A (en) Bispecific t cell activating antigen binding molecules
TN2018000325A1 (en) ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123.
PH12022553489A1 (en) Antibodies binding to cd3 and folr1
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
WO2023079102A3 (en) Novel peptides
MX2026000851A (es) Anticuerpos que se unen a cd3
MX2024013063A (es) Terapia combinada de anticuerpos biespecificos contra la molecula de adhesion a celulas relacionadas con el antigeno carcinoembrionario 5 (ceacam5) y cumulo de diferenciacion 47 (cd47) y anticuerpos biespecificos contra la molecula de adhesion a celulas relacionadas con el antigeno carcinoembrionario 5 (ceacam5) y cumulo de diferenciacion 3 (cd3)